Theravance Biopharma price target raised to $20 from $15 at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Theravance Biopharma (TBPH) to $20 from $15 and keeps a Buy rating on the shares following the Q3 report. Net sales of Yupelri reached an all-time high of $71.4M, the analyst tells investors in a research note. The firm upped estimates for 2026 and beyond.